Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > NO ONE GIVING THEIR .02 cents WORTH? .01 CENTS WORTH

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Jul 17, 2021 10:18am

112 Views

Post# 33565036

RE:NO ONE GIVING THEIR .02 cents WORTH? .01 CENTS WORTH

losingmyshirt wrote: THE PUMPERS HAVE PACKED THEIR BAGS AND HAVE CALLED IT DONE.

Friday could be the BIG DAY. It has been long awaited.

What Kalytera needs is Massive Volume. Will the Friday SELL-OFF show us .01?

Go KALYTERA!

Kaboom!

.02 cents is about double what your advice is worth.